| Literature DB >> 32552873 |
Takumi Hasegawa1, Tomoya Iga2, Daisuke Takeda2, Rika Amano2, Izumi Saito2, Yasumasa Kakei2, Junya Kusumoto2, Akira Kimoto2, Akiko Sakakibara2, Masaya Akashi2.
Abstract
BACKGROUND: Prognostic biomarkers provide essential information about a patient's overall outcome. However, existing biomarkers are limited in terms of either sample collection, such as requiring tissue specimens, or the process, such as prolonged time for analysis. In view of the need for convenient and non-invasive prognostic biomarkers for oral cancer, we aimed to investigate the prognostic values of neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio in patient survival. We also aimed to explore the associations of these ratios with the clinicopathologic characteristics of Japanese oral squamous cell carcinoma patients.Entities:
Keywords: Disease-specific survival; Lymphocyte-to-monocyte ratio; Neutrophil-to-lymphocyte ratio; Oral squamous cell carcinoma; Overall survival; Platelet-to-lymphocyte ratio
Year: 2020 PMID: 32552873 PMCID: PMC7302163 DOI: 10.1186/s12885-020-07063-1
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Characteristics of patients according to NLR
| Variables | NLR | ||
|---|---|---|---|
| Low, n (%) | High, n (%) | ||
| Number of patients | 233 (53.8) | 200 (46.2) | |
| Sex | |||
| Male | 142 (60.9) | 104 (52.0) | 0.065 * |
| Female | 91 (39.1) | 96 (48.0) | |
| Age | |||
| Range (Years) | 27–98 | 22–92 | |
| Mean ± SD | 65.7 ± 13.0 | 67.0 ± 14.0 | 0.170 ** |
| ≥ 64 | 95 (40.8) | 78 (39.0) | 0.768 * |
| ≤ 65 | 138 (59.2) | 122 (61.0) | |
| Smoking history | |||
| No | 112 (48.1) | 107 (53.5) | 0.179 * |
| Yes | 47 (20.2) | 22 (11.0) | |
| Unknown | 74 (31.8) | 71 (35.5) | |
| Alcohol consumption | |||
| No | 81 (34.8) | 71 (35.5) | 0.472 * |
| Yes | 76 (32.6) | 55 (27.5) | |
| Unknown | 76 (32.6) | 74 (37.0) | |
| Performance status | |||
| 0 | 131 (56.2) | 96 (48.0) | 0.121 * |
| ≥ 1 | 101 (43.4) | 101 (50.5) | |
| unknown | 1 (0.4) | 3 (1.5) | |
| Subsite | |||
| Tongue | 116 (49.8) | 95 (47.5) | 0.700 * |
| Other | 117 (50.2) | 105 (52.5) | |
| T classification | |||
| 1, 2 | 167 (71.7) | 134 (67.0) | 0.297 * |
| 3, 4a/b | 66 (28.3) | 66 (33.0) | |
| N classification | |||
| 0 | 168 (72.1) | 128 (64.0) | 0.078 * |
| Others | 65 (27.9) | 72 (36.0) | |
| Pathological status | |||
| Pathological extranodal extensions | |||
| ENE - | 44 (57.9) | 45 (54.9) | 0.750 * |
| ENE + | 32 (42.1) | 37 (45.1) | |
| Number of pathological lymph node metastases | |||
| 0, 1 | 101 (69.2) | 72 (57.1) | 0.044 * |
| ≥ 2 | 45 (30.8) | 54 (42.9) | |
| Surgical margins | |||
| Negative | 180 (77.3) | 147 (73.5) | 0.358 * |
| Involved margins | 49 (21.0) | 50 (25.0) | |
| Unknown | 4 (1.7) | 3 (1.5) | |
| Histological differentiation | |||
| Well differentiated | 135 (57.9) | 126 (63.0) | 0.372 * |
| Moderately or poorly differentiated | 95 (40.8) | 73 (36.5) | |
| Unknown | 3 (1.3) | 1 (0.5) | |
ENE Extranodal extension; NLR Neutrophil-lymphocyte ratio
*: Fisher’s exact test **: Mann–Whitney U test
Characteristics of patients according to LMR
| Variables | LMR | ||
|---|---|---|---|
| Low, n (%) | High, n (%) | ||
| Number of patients | 180 (41.6) | 253 (58.4) | |
| Sex | |||
| Male | 112 (62.2) | 134 (53.0) | 0.062 * |
| Female | 68 (37.8) | 119 (47.0) | |
| Age | |||
| Range (Years) | 22–92 | 23–98 | |
| Mean ± SD | 67.8 ± 12.9 | 65.3 ± 13.8 | 0.057 ** |
| ≥ 64 | 66 (36.7) | 107 (42.3) | 0.273 * |
| ≤ 65 | 114 (63.3) | 146 (57.7) | |
| Smoking history | |||
| No | 94 (52.2) | 125 (49.4) | 0.680 * |
| Yes | 32 (17.8) | 37 (14.6) | |
| Unknown | 54 (30.0) | 91 (36.0) | |
| Alcohol consumption | |||
| No | 63 (35.0) | 89 (35.2) | 0.282 * |
| Yes | 63 (35.0) | 68 (26.9) | |
| Unknown | 54 (30.0) | 96 (37.9) | |
| Performance status | |||
| 0 | 78 (43.3) | 149 (58.9) | 0.002 * |
| ≥ 1 | 100 (55.6) | 102 (40.3) | |
| Unknown | 2 (1.1) | 2 (0.8) | |
| Subsite | |||
| Tongue | 75 (41.7) | 136 (53.8) | 0.015 * |
| Other | 105 (58.3) | 117 (46.2) | |
| T classification | |||
| 1, 2 | 111 (61.7) | 190 (75.1) | 0.003 * |
| 3, 4a/b | 69 (38.3) | 63 (24.9) | |
| N classification | |||
| 0 | 110 (61.1) | 186 (73.5) | 0.007 * |
| Others | 70 (38.9) | 67 (26.5) | |
| Pathological status | |||
| Pathological extranodal extension | |||
| ENE - | 41 (52.6) | 48 (60.0) | 0.423 * |
| ENE + | 37 (47.4) | 32 (40.0) | |
| Number of pathological lymph node metastases | |||
| 0, 1 | 74 (58.3) | 99 (68.3) | 0.101 * |
| ≥ 2 | 53 (41.7) | 46 (31.7) | |
| Surgical margins | |||
| Negative | 133 (73.9) | 194 (76.7) | 0.417 * |
| Involved margins | 45 (25.0) | 54 (21.3) | |
| Unknown | 2 (1.1) | 5 (2.0) | |
| Histological differentiation | |||
| Well differentiated | 107 (59.4) | 154 (60.9) | 0.736 * |
| Moderately or poorly differentiated | 72 (40.0) | 96 (37.9) | |
| Unknown | 1 (0.6) | 3 (1.2) | |
ENE Extranodal extension; LMR Lymphocyte-to-monocyte ratio
*: Fisher’s exact test **: Mann–Whitney U test
Characteristics of patients according to PLR
| Variables | PLR | ||
|---|---|---|---|
| Low, n (%) | High, n (%) | ||
| Number of patients | 240 (55.4) | 193 (44.6) | |
| Sex | |||
| Male | 156 (65.0) | 90 (46.6) | < 0.001 * |
| Female | 84 (35.0) | 103 (53.4) | |
| Age | |||
| Range (Years) | 27–98 | 22–92 | |
| Mean ± SD | 66.1 ± 12.7 | 66.6 ± 14.4 | 0.253 ** |
| ≥ 64 | 100 (41.7) | 73 (37.8) | 0.431 * |
| ≤ 65 | 140 (58.3) | 120 (62.2) | |
| Smoking history | |||
| No | 115 (47.9) | 104 (53.9) | 0.002 * |
| Yes | 51 (21.3) | 18 (9.3) | |
| Unknown | 74 (30.8) | 71 (36.8) | |
| Alcohol consumption | |||
| No | 84 (35.0) | 68 (35.2) | 0.473 * |
| Yes | 78 (32.5) | 53 (27.5) | |
| Unknown | 78 (32.5) | 72 (37.3) | |
| Performance status | |||
| 0 | 135 (56.3) | 92 (47.7) | 0.081 * |
| ≥ 1 | 103 (38.8) | 99 (41.3) | |
| Unknown | 2 (0.8) | 2 (1.0) | |
| Subsite | |||
| Tongue | 126 (52.5) | 85 (44.0) | 0.083 * |
| Other | 114 (47.5) | 108 (56.0) | |
| T classification | |||
| 1, 2 | 176 (73.3) | 125 (64.8) | 0.059 * |
| 3, 4a/b | 64 (26.7) | 68 (35.2) | |
| N classification | |||
| 0 | 168 (70.0) | 128 (66.3) | 0.467 * |
| Others | 72 (30.0) | 65 (33.7) | |
| Pathological status | |||
| Pathological extranodal extension | |||
| ENE - | 49 (57.6) | 40 (54.8) | 0.750 * |
| ENE + | 36 (42.4) | 33 (45.2) | |
| Number of pathological lymph node metastases | |||
| 0, 1 | 94 (63.9) | 79 (63.2) | 0.900 * |
| ≥ 2 | 53 (36.1) | 46 (36.8) | |
| Surgical margins | |||
| Negative | 184 (76.7) | 143 (74.1) | 0.421 * |
| Involved margins | 51 (21.3) | 48 (24.9) | |
| Unknown | 5 (2.1) | 2 (1.0) | |
| Histological differentiation | |||
| Well differentiated | 142 (59.2) | 119 (61.7) | 0.691 * |
| Moderately or poorly differentiated | 95 (39.6) | 73 (37.8) | |
| Unknown | 3 (1.3) | 1 (0.5) | |
ENE Extranodal extension; PLR Platelet-to-lymphocyte ratio
*: Fisher’s exact test **: Mann–Whitney U test
Characteristics of patients according to DSS and OS
| Variables | n (%) | 5-year DSS (%) | 5-year OS (%) | ||
|---|---|---|---|---|---|
| Sex | |||||
| Male | 246 (56.8) | 83.1 | 0.684 * | 74.6 | 0.126 * |
| Female | 187 (43.2) | 84.8 | 80.5 | ||
| Age | |||||
| Range (Years) | 22–98 | ||||
| Mean ± SD | 66.3 ± 13.5 | ||||
| ≥ 64 | 173 (40.0) | 79.9 | 0.120 * | 73.7 | 0.608 * |
| ≤ 65 | 260 (60.0) | 86.6 | 79.6 | ||
| Smoking history | |||||
| No | 219 (50.6) | 88.2 | 0.548 * | 82.5 | 0.179 * |
| Yes | 69 (15.9) | 85.3 | 76.7 | ||
| Unknown | 145 (33.5) | ||||
| Alcohol consumption | |||||
| No | 152 (35.1) | 83.9 | 0.105 * | 77.3 | 0.391 * |
| Yes | 131 (30.3) | 91.2 | 84.6 | ||
| Unknown | 150 (34.6) | ||||
| Performance status | |||||
| 0 | 227 (52.4) | 85.2 | 0.274 * | 79.6 | 0.025 * |
| ≥ 1 | 202 (46.7) | 81.9 | 74.3 | ||
| unknown | 4 (0.9) | ||||
| Subsite | |||||
| Tongue | 211 (48.7) | 85.4 | 0.311 * | 80.2 | 0.083 * |
| Other | 222 (51.3) | 82.2 | 73.9 | ||
| T classification | |||||
| 1, 2 | 301 (69.5) | 88.5 | < 0.001 * | 83.1 | < 0.001 * |
| 3, 4a/b | 132 (30.5) | 72.2 | 62.4 | ||
| N classification | |||||
| 0 | 296 (68.4) | 91.6 | < 0.001 * | 85.6 | < 0.001 * |
| Others | 137 (31.6) | 66.4 | 58.5 | ||
| NLR | |||||
| Low (2.22 <) | 233 (53.8) | 91.4 | < 0.001 * | 84.6 | < 0.001 * |
| High (2.22 ≥) | 200 (46.2) | 75.5 | 68.8 | ||
| LMR | |||||
| Low (4.35 <) | 253 (58.4) | 76.3 | < 0.001 * | 70.0 | 0.001 * |
| High (4.35 ≥) | 180 (41.6) | 89.1 | 82.1 | ||
| PLR | |||||
| Low (134.3 <) | 240 (55.4) | 86.6 | 0.044 * | 78.4 | 0.232 * |
| High (134.3 ≥) | 193 (44.6) | 80.6 | 75.6 | ||
| Pathological status | |||||
| Pathological extra nodal metastasis | |||||
| ENE - | 89 (56.3) | 72.8 | 0.004 * | 63.7 | 0.012 * |
| ENE + | 69 (43.7) | 50.7 | 42.4 | ||
| Number of pathological lymph node metastases | |||||
| 0, 1 | 173 (63.6) | 84.7 | < 0.001 * | 78.1 | < 0.001 * |
| ≥ 2 | 99 (36.4) | 60.8 | 50.1 | ||
| Surgical margins | |||||
| Negative | 314 (72.5) | 85.5 | 0.030 * | 78.7 | 0.043 * |
| Involved margins | 112 (25.9) | 79.1 | 72.1 | ||
| unknown | 7 (1.6) | ||||
| Histological differentiation | |||||
| Well differentiated | 261 (60.3) | 91.5 | < 0.001 * | 83.3 | 0.001 * |
| Moderately or poorly differentiated | 168 (38.8) | 71.7 | 67.0 | ||
| unknown | 4 (0.9) | ||||
DSS Disease- specific survival; ENE Extranodal extension; LMR Lymphocyte-to-monocyte ratio; NLR Neutrophil-to-lymphocyte ratio; OS Overall survival; PLR Platelet-to-lymphocyte ratio
*: Log-rank test
Fig. 1Cumulative disease-specific survival (DSS) rates in patients with high and low neutrophil-to-lymphocyte ratio (NLR). The 5-year DSS rates of patients with high and low NLR were 75.5 and 91.4%, respectively
Fig. 2Cumulative disease-specific survival (DSS) rates in patients with high and low lymphocyte-to-monocyte ratio (LMR). The 5-year DSS rates of patients with high and low LMR were 89.1 and 76.3%, respectively
Fig. 3Cumulative disease-specific survival (DSS) rates in patients with high and low platelet-to-lymphocyte ratio (PLR). The 5-year DSS rates of patients with high and low PLR were 80.6 and 86.6%, respectively
Results of multivariate Cox proportional hazards analysis of predictors of disease-specific survival
| Variable | Hazards ratio | 95% CI | ||
|---|---|---|---|---|
| Lower | Upper | |||
| High NLR (2.22 ≥) | < 0.001 | 2.87 | 1.59 | 5.19 |
| Moderately or poorly differentiated histology | < 0.001 | 2.37 | 1.32 | 4.25 |
| Extranodal extension | 0.016 | 1.95 | 1.13 | 3.35 |
CI Confidence interval; NLR Neutrophil-to-lymphocyte ratio
Results of multivariate Cox proportional hazards analysis of predictors of overall survival (OS)
| Variable | Hazards ratio | 95% CI | ||
|---|---|---|---|---|
| Lower | Upper | |||
| High NLR (2.22 ≥) | < 0.001 | 2.30 | 1.42 | 3.72 |
| Moderately or poorly differentiated histology | 0.025 | 1.72 | 1.07 | 2.76 |
| Extra nodal extension | 0.013 | 1.79 | 1.13 | 2.84 |
CI Confidence interval; NLR Neutrophil-to-lymphocyte ratio